Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 233

1.

Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes.

Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T.

Semin Oncol. 2019 Feb;46(1):83-99. doi: 10.1053/j.seminoncol.2019.01.002. Epub 2019 Jan 26. Review.

PMID:
30738604
2.

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2018 Oct 2;9(77):34641. doi: 10.18632/oncotarget.26214. eCollection 2018 Oct 2.

3.

Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years.

Sackstein PE, O'Neil DS, Neugut AI, Chabot J, Fojo T.

Semin Oncol. 2018 Aug;45(4):249-258. doi: 10.1053/j.seminoncol.2018.07.001. Epub 2018 Oct 19.

4.

Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Di Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K.

Cancer. 2019 Feb 1;125(3):406-415. doi: 10.1002/cncr.31816. Epub 2018 Oct 20.

PMID:
30341983
5.

Desperation Oncology.

Fojo T.

Semin Oncol. 2018 Jun;45(3):105-106. doi: 10.1053/j.seminoncol.2018.08.001. Epub 2018 Oct 6. No abstract available.

PMID:
30301565
6.

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.

Del Rivero J, Edgerly M, Ward J, Madan RA, Balasubramaniam S, Fojo T, Gramza AW.

Oncologist. 2019 Jan;24(1):16-e14. doi: 10.1634/theoncologist.2018-0452. Epub 2018 Oct 8.

7.

Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.

Bauml JM, Vinnakota R, Anna Park YH, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K.

J Natl Cancer Inst. 2019 May 1;111(5):490-497. doi: 10.1093/jnci/djy133.

PMID:
30239887
8.

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.

Laderian B, Fojo T.

Semin Oncol. 2017 Dec;44(6):395-403. doi: 10.1053/j.seminoncol.2018.03.006. Epub 2018 Mar 26. Review.

PMID:
29935901
9.

Continued Tumor Reduction of Metastatic Pheochromocytoma/Paraganglioma Harboring Succinate Dehydrogenase Subunit B Mutations with Cyclical Chemotherapy.

Jawed I, Velarde M, Därr R, Wolf KI, Adams K, Venkatesan AM, Balasubramaniam S, Poruchynsky MS, Reynolds JC, Pacak K, Fojo T.

Cell Mol Neurobiol. 2018 Jul;38(5):1099-1106. doi: 10.1007/s10571-018-0579-4. Epub 2018 Apr 5.

10.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

11.

The evidence framework for precision cancer medicine.

Moscow JA, Fojo T, Schilsky RL.

Nat Rev Clin Oncol. 2018 Mar;15(3):183-192. doi: 10.1038/nrclinonc.2017.186. Epub 2017 Dec 19. Review.

PMID:
29255239
12.

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using 64Cu-plerixafor PET.

Weiss ID, Huff LM, Evbuomwan MO, Xu X, Dang HD, Velez DS, Singh SP, Zhang HH, Gardina PJ, Lee JH, Lindenberg L, Myers TG, Paik CH, Schrump DS, Pittaluga S, Choyke PL, Fojo T, Farber JM.

Oncotarget. 2017 Aug 4;8(43):73387-73406. doi: 10.18632/oncotarget.19945. eCollection 2017 Sep 26. Erratum in: Oncotarget. 2018 Oct 2;9(77):34641.

13.

Neutral evolution of drug resistant colorectal cancer cell populations is independent of their KRAS status.

Blagoev KB, Wilkerson J, Burotto M, Kim C, Espinal-Domínguez E, García-Alfonso P, Alimchandani M, Miettinen M, Blanco-Codesido M, Fojo T.

PLoS One. 2017 Oct 5;12(10):e0175484. doi: 10.1371/journal.pone.0175484. eCollection 2017.

14.

Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.

Enzler T, Fojo T.

Semin Oncol. 2017 Apr;44(2):141-156. doi: 10.1053/j.seminoncol.2017.07.001. Epub 2017 Jul 25. Review.

PMID:
28923213
15.

Cancer therapies and the problem of me too many.

Fojo T.

Semin Oncol. 2017 Apr;44(2):113. doi: 10.1053/j.seminoncol.2017.06.004. Epub 2017 Jul 6. No abstract available.

PMID:
28923208
16.

A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.

Burotto M, Edgerly M, Velarde M, Balasubramaniam S, Drabkin H, Gormaz JG, O'Sullivan C, Madan R, Fojo T.

Oncologist. 2017 Aug;22(8):888-e84. doi: 10.1634/theoncologist.2017-0211. Epub 2017 Jul 5.

17.

Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.

Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R.

Ann Oncol. 2017 Aug 1;28(8):1738-1750. doi: 10.1093/annonc/mdx110. Review.

18.

Pseudo-progressing to an unmet need.

Fojo T.

Semin Oncol. 2017 Feb;44(1):1-2. doi: 10.1053/j.seminoncol.2017.02.012. Epub 2017 Feb 24. No abstract available.

PMID:
28395757
19.

Anti-Hu paraneoplastic brainstem encephalitis caused by a pancreatic neuroendocrine tumor presenting with central hypoventilation.

Najjar M, Taylor A, Agrawal S, Fojo T, Merkler AE, Rosenblum MK, Lennihan L, Kluger MD.

J Clin Neurosci. 2017 Jun;40:72-73. doi: 10.1016/j.jocn.2017.02.015. Epub 2017 Feb 27.

PMID:
28256369
20.

The high cost of ignorance in oncology.

Fojo T.

Semin Oncol. 2016 Dec;43(6):623-624. doi: 10.1053/j.seminoncol.2016.11.010. Epub 2016 Nov 15. No abstract available.

21.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13.

PMID:
27979599
22.

Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome.

Därr R, Nambuba J, Del Rivero J, Janssen I, Merino M, Todorovic M, Balint B, Jochmanova I, Prchal JT, Lechan RM, Tischler AS, Popovic V, Miljic D, Adams KT, Prall FR, Ling A, Golomb MR, Ferguson M, Nilubol N, Chen CC, Chew E, Taïeb D, Stratakis CA, Fojo T, Yang C, Kebebew E, Zhuang Z, Pacak K.

Endocr Relat Cancer. 2016 Dec;23(12):899-908. Epub 2016 Sep 27.

23.

Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.

Payabyab EC, Balasubramaniam S, Edgerly M, Velarde M, Merino MJ, Venkatesan AM, Leuva H, Litman T, Bates SE, Fojo T.

Clin Cancer Res. 2016 Oct 15;22(20):4989-5000.

24.

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT-PET after first cycle and MRI in response assessment.

O'Sullivan CC, Lindenberg M, Bryla C, Patronas N, Peer CJ, Amiri-Kordestani L, Davarpanah N, Gonzalez EM, Burotto M, Choyke P, Steinberg SM, Liewehr DJ, Figg WD, Fojo T, Balasubramaniam S, Bates SE.

Breast Cancer Res Treat. 2016 Nov;160(1):51-59. Epub 2016 Sep 12.

25.

BEZ235: When Promising Science Meets Clinical Reality.

Pongas G, Fojo T.

Oncologist. 2016 Sep;21(9):1033-4. doi: 10.1634/theoncologist.2016-0243. Epub 2016 Aug 26. No abstract available.

26.

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials.

Kumar H, Fojo T, Mailankody S.

JAMA Oncol. 2016 Sep 1;2(9):1238-40. doi: 10.1001/jamaoncol.2016.0931. No abstract available.

27.

Female fertility following dose-adjusted EPOCH-R chemotherapy in primary mediastinal B-cell lymphomas.

Gharwan H, Lai C, Grant C, Dunleavy K, Steinberg SM, Shovlin M, Fojo T, Wilson WH.

Leuk Lymphoma. 2016 Jul;57(7):1616-24. doi: 10.3109/10428194.2015.1118476. Epub 2016 May 17.

PMID:
27183887
28.

Are patients with hormonally functional phaeochromocytoma and paraganglioma initially receiving a proper adrenoceptor blockade? A retrospective cohort study.

Luiz HV, Tanchee MJ, Pavlatou MG, Yu R, Nambuba J, Wolf K, Prodanov T, Wesley R, Adams K, Fojo T, Pacak K.

Clin Endocrinol (Oxf). 2016 Jul;85(1):62-9. doi: 10.1111/cen.13066. Epub 2016 Apr 15.

29.

Precision oncology: a strategy we were not ready to deploy.

Fojo T.

Semin Oncol. 2016 Feb;43(1):9-12. doi: 10.1053/j.seminoncol.2016.01.005. Epub 2016 Jan 28. No abstract available.

PMID:
26970119
30.

Moving a pioneer journal into the future.

Fojo T.

Semin Oncol. 2016 Feb;43(1):1. doi: 10.1053/j.seminoncol.2016.01.004. Epub 2016 Jan 26. No abstract available.

PMID:
26970116
31.

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

Bates SE, Fojo T.

Nat Rev Clin Oncol. 2016 Apr;13(4):205-6. doi: 10.1038/nrclinonc.2016.22. Epub 2016 Feb 23. No abstract available.

PMID:
26902963
32.

Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting.

Massey PR, Wang R, Prasad V, Bates SE, Fojo T.

Oncologist. 2016 Mar;21(3):261-8. doi: 10.1634/theoncologist.2015-0516. Epub 2016 Feb 17.

33.

Precision oncology: origins, optimism, and potential.

Prasad V, Fojo T, Brada M.

Lancet Oncol. 2016 Feb;17(2):e81-e86. doi: 10.1016/S1470-2045(15)00620-8. Review.

PMID:
26868357
34.

Price, value, and the cost of cancer drugs.

Fojo T, Lo AW.

Lancet Oncol. 2016 Jan;17(1):3-5. doi: 10.1016/S1470-2045(15)00564-1. Epub 2015 Dec 23. No abstract available.

PMID:
26758749
35.

CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.

Turkova H, Prodanov T, Maly M, Martucci V, Adams K, Widimsky J Jr, Chen CC, Ling A, Kebebew E, Stratakis CA, Fojo T, Pacak K.

Endocr Pract. 2016 Mar;22(3):302-14. doi: 10.4158/EP15725.OR. Epub 2015 Nov 2.

PMID:
26523625
36.

Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.

Jawed I, Wilkerson J, Prasad V, Duffy AG, Fojo T.

JAMA Oncol. 2015 Sep;1(6):787-95. doi: 10.1001/jamaoncol.2015.1790.

PMID:
26181239
37.

Pancreatic cancer: Targeting KRAS and the vitamin D receptor via microtubules.

Basseville A, Bates S, Fojo T.

Nat Rev Clin Oncol. 2015 Aug;12(8):442-4. doi: 10.1038/nrclinonc.2015.125. Epub 2015 Jul 14. No abstract available.

PMID:
26169922
38.

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.

Burotto M, Edgerly M, Poruchynsky M, Velarde M, Wilkerson J, Kotz H, Bates S, Balasubramaniam S, Fojo T.

Oncologist. 2015 Jul;20(7):725-6. doi: 10.1634/theoncologist.2015-0104. Epub 2015 Jun 3.

39.

Multiplying therapies and reducing toxicity in metastatic melanoma.

Massey PR, Prasad V, Figg WD, Fojo T.

Cancer Biol Ther. 2015;16(7):1014-8. doi: 10.1080/15384047.2015.1046650. Epub 2015 May 27.

40.

Succinate dehydrogenase gene mutations in cardiac paragangliomas.

Martucci VL, Emaminia A, del Rivero J, Lechan RM, Magoon BT, Galia A, Fojo T, Leung S, Lorusso R, Jimenez C, Shulkin BL, Audibert JL, Adams KT, Rosing DR, Vaidya A, Dluhy RG, Horvath KA, Pacak K.

Am J Cardiol. 2015 Jun 15;115(12):1753-9. doi: 10.1016/j.amjcard.2015.03.020. Epub 2015 Mar 24.

41.

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.

Bates SE, Eisch R, Ling A, Rosing D, Turner M, Pittaluga S, Prince HM, Kirschbaum MH, Allen SL, Zain J, Geskin LJ, Joske D, Popplewell L, Cowen EW, Jaffe ES, Nichols J, Kennedy S, Steinberg SM, Liewehr DJ, Showe LC, Steakley C, Wright J, Fojo T, Litman T, Piekarz RL.

Br J Haematol. 2015 Jul;170(1):96-109. doi: 10.1111/bjh.13400. Epub 2015 Apr 19.

42.

Non-inferiority trials: why oncologists must remain wary.

Burotto M, Prasad V, Fojo T.

Lancet Oncol. 2015 Apr;16(4):364-6. doi: 10.1016/S1470-2045(15)70129-4. No abstract available.

PMID:
25846084
43.

Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.

Burotto M, Manasanch EE, Wilkerson J, Fojo T.

Oncologist. 2015 Apr;20(4):400-10. doi: 10.1634/theoncologist.2014-0154. Epub 2015 Mar 20.

44.

Brain metastasis in patients with adrenocortical carcinoma: a clinical series.

Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly M, Fojo T.

J Clin Endocrinol Metab. 2015 Feb;100(2):331-6. doi: 10.1210/jc.2014-2650. Epub 2014 Nov 20.

45.

Decade in review-funding in cancer research: National Cancer Institute awards-a work in progress.

Fojo T, Giannakakou P.

Nat Rev Clin Oncol. 2014 Nov;11(11):634-6. doi: 10.1038/nrclinonc.2014.173. Epub 2014 Oct 14. No abstract available.

PMID:
25311348
46.

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T.

Cancer Res. 2014 Sep 1;74(17):4653-62. doi: 10.1158/0008-5472.CAN-14-0420.

47.

Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Fojo T, Mailankody S, Lo A.

JAMA Otolaryngol Head Neck Surg. 2014 Dec;140(12):1225-36. doi: 10.1001/jamaoto.2014.1570.

PMID:
25068501
48.

The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.

Schovanek J, Martucci V, Wesley R, Fojo T, Del Rivero J, Huynh T, Adams K, Kebebew E, Frysak Z, Stratakis CA, Pacak K.

BMC Cancer. 2014 Jul 21;14:523. doi: 10.1186/1471-2407-14-523.

49.

Current approaches and recent developments in the management of head and neck paragangliomas.

Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler JR Jr, Pacak K.

Endocr Rev. 2014 Oct;35(5):795-819. doi: 10.1210/er.2014-1026. Epub 2014 Jul 17. Review.

50.

Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.

Burotto M, Wilkerson J, Stein W, Motzer R, Bates S, Fojo T.

PLoS One. 2014 May 5;9(5):e96316. doi: 10.1371/journal.pone.0096316. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e105179.

Supplemental Content

Support Center